February 1, 2024 07:18 AM EST
Financing
Cell/Gene Tx

Kyver­na seeks $182M IPO as biotech runs mul­ti­ple au­toim­mune CAR-T tri­als

Kyle LaHucik

Senior Reporter

Kyver­na Ther­a­peu­tics aims to be the fifth biotech to IPO in 2024 as the au­toim­mune CAR-T cell ther­a­py mak­er sets its sights on $182 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times